Content area

|
|

Primær forebyggelse af kardiovaskulære hændelser med acetylsalicylsyre hos patienter med type 2-diabetes mellitus

Forfatter(e)
Victoria Rosberg1, Erik Lerkevang Grove2, 3, Hans Erik Bøtker2, 3, Steen Dalby Kristensen2, 3 & Manan Pareek1, 2
1) Kardiologisk Afdeling, Nordsjællands Hospital, Hillerød2) Hjertesygdomme, Aarhus Universitetshospital3) Institut for Klinisk Medicin, Health, Aarhus Universitet

Ugeskr Læger 2019;181:V03190205
Reference: 
Ugeskr Læger 2019;181:V03190205
Blad nummer: 

Victoria Rosberg, Erik Lerkevang Grove, Hans Erik Bøtker, Steen Dalby Kristensen & Manan Pareek:

Acetylsalicylic acid for primary prevention of cardiovascular events in patients with Type 2 diabetes mellitus

Ugeskr Læger 2019;181:V03190205

This review assesses the latest evidence and guidelines related to the use of aspirin for primary prevention among patients with Type 2 diabetes (T2D) without overt cardiovascular disease. The global burden of T2D is steadily increasing and most deaths among patients with T2D are attributed to cardiovascular events. Furthermore, several haemostatic abnormalities have been shown in this group of patients, including increased platelet turnover and aggregation.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Holger Ahler M. Therkildsen | 29/09
1 Kommentar
af Mats Lindberg | 29/09
1 Kommentar
af Anne Amalie Elgaard Thorup | 28/09
1 Kommentar
af Henrik Harboe | 28/09
1 Kommentar
af Svend Nielsen | 27/09
4 kommentarer
af Nini Katja Møller | 26/09
1 Kommentar
af Niels Rud Haagensen | 25/09
10 kommentarer